Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R VanDevanter

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Infection and Immunity|May 29, 1998
Differential effects of myeloperoxidase-derived oxidants on Escherichia coli DNA replicationH Rosen, B R Michel, D R vanDevanter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 4, 2016
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosisD R VanDevanter, P A Flume, N Morris, et al.
Cancer Genetics and Cytogenetics|November 1, 1991
Trisomy 8 in primary esthesioneuroblastomaD R VanDevanter, D George, M A McNutt, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1990
Loss of DNA-membrane interactions and cessation of DNA synthesis in myeloperoxidase-treated Escherichia coliH Rosen, J Orman, R M Rakita, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 30, 2025
Differences in pulmonary exacerbation risks among CF subpopulationsD R VanDevanter, C O'Rourke, M W Konstan, et al.
Journal of the National Cancer Institute|December 5, 1990
Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivoD R VanDevanter, V D Piaskowski, J T Casper, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 2, 2011
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpointD R Vandevanter, A Yegin, W J Morgan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 22, 2010
Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpointM W Konstan, J S Wagener, A Yegin, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 30, 2019
Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infectionD R VanDevanter, I Gonda, J Dahms, et al.
Journal of Clinical Microbiology|July 1, 1996
Detection and analysis of diverse herpesviral species by consensus primer PCRD R VanDevanter, P Warrener, L Bennett, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Infection and Immunity|May 29, 1998
Differential effects of myeloperoxidase-derived oxidants on Escherichia coli DNA replicationH Rosen, B R Michel, D R vanDevanter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 4, 2016
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosisD R VanDevanter, P A Flume, N Morris, et al.
Cancer Genetics and Cytogenetics|November 1, 1991
Trisomy 8 in primary esthesioneuroblastomaD R VanDevanter, D George, M A McNutt, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1990
Loss of DNA-membrane interactions and cessation of DNA synthesis in myeloperoxidase-treated Escherichia coliH Rosen, J Orman, R M Rakita, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 30, 2025
Differences in pulmonary exacerbation risks among CF subpopulationsD R VanDevanter, C O'Rourke, M W Konstan, et al.
Journal of the National Cancer Institute|December 5, 1990
Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivoD R VanDevanter, V D Piaskowski, J T Casper, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 2, 2011
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpointD R Vandevanter, A Yegin, W J Morgan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 22, 2010
Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpointM W Konstan, J S Wagener, A Yegin, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 30, 2019
Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infectionD R VanDevanter, I Gonda, J Dahms, et al.
Journal of Clinical Microbiology|July 1, 1996
Detection and analysis of diverse herpesviral species by consensus primer PCRD R VanDevanter, P Warrener, L Bennett, et al.
Pageof 4